Discontinued Operations (Details) (USD $)	3 Months Ended		9 Months Ended			0 Months Ended	3 Months Ended			9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Sep. 01, 2014 Antioxidant, Ibuprofen and Propofol Assets	Sep. 30, 2014 Antioxidant, Ibuprofen and Propofol Assets	Jun. 30, 2014 Antioxidant, Ibuprofen and Propofol Assets	Sep. 30, 2013 Antioxidant, Ibuprofen and Propofol Assets	Sep. 30, 2014 Antioxidant, Ibuprofen and Propofol Assets	Sep. 30, 2013 Antioxidant, Ibuprofen and Propofol Assets
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds from divestitures, net			$ 104,718,000	$ 0		$ 104,700,000
Net sales							38,025,000		57,442,000	154,273,000	169,825,000
(Loss) income from discontinued operations							(7,752,000)		842,000	(90,439,000)	7,013,000
Income tax (benefit) expense							(1,073,000)		311,000	(21,966,000)	2,019,000
(Loss) income from discontinued operations (net of tax)	(6,679,000)	531,000	(68,473,000)	4,994,000			(6,679,000)		531,000	(68,473,000)	4,994,000
Loss on disposal of businesses			85,515,000	0			4,800,000	80,700,000
Loss on disposal of businesses, net of tax							3,600,000	61,000,000
Cumulative foreign currency translation gains included in pre-tax impairment charge										17,800,000
Other accounts receivable	$ 41,261,000		$ 41,261,000		$ 45,094,000		$ 8,500,000			$ 8,500,000